Saturday 7 November 2026 Export SPTX’s income statement to Excel — free account

Seaport Therapeutics, Inc

SPTX Healthcare Biotechnology

EPS: +94.8%
Free cash flow: −43.8%

Quarter to September 2026, against a year earlier

Insider buying

21.18 0.79 +3.87%

Follow SPTX

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 20.14

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	1	1	—	—	—	—	1
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 74.22%

Capital & Financial Ratios $m

Size

Market Cap 1,090.00

Revenue ttm —

Net income ttm (138.54)

Free cash flow ttm (95.64)

Net debt Q (290.43)

Valuation

P/E 0.00

Forward P/E —

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.85

Financial health

Current ratio Q 17.48

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q —

Operating income growth Q −19.28%

EPS, this year +86.89%

EPS, next year A +40.61%

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A +57.09%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	—	309	216	290
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	—	310	223	299

	2023	2024	2025	Q'26
Payables	—	5	2	6
ST’ Debt	—	0	0	—
Other	—	—	—	—
	—	11	13	17

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	—
Earnings	—	—	—
Book Value	—	—	—

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.58 Actual −0.49

−1.97 −1.55 −1.13 −0.72 −0.30

Q2 FY26 Miss −1.07

Q3 FY26 Beat +0.09

Q4 FY26 — Feb 1

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY26	−0.71	−1.78	Miss by 1.07
Q3 FY26	−0.58	−0.49	Beat by 0.09
Q4 FY26	−0.61	—	Reports 1 February 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(10.34)	(1.78)	(0.49)	—	—
’25	(5.65)	(6.40)	(9.43)	(10.06)	(31.54)

Fiscal quarters ending in the months shown.

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(26)	(23)	—	—
’25	(20)	(15)	(16)	(27)	(78)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(26)	(23)	—	—
’25	(20)	(16)	(16)	(27)	(78)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—	—		—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—	—		—	Powerpack Seaport Therapeutics, Inc’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	—	—	—	—	—	—	(47)	(74)	(137)		+58.1%
	EBT margin, %	—	—	—	—	—	—	—	—	0.00	0.00	0.00		0.0 pt
	Net income	—	—	—	—	—	—	—	—	(47)	(75)	(139)		+59.7%
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	—	—	0.00	0.00	0.00		n/m
	Earnings	—	—	—	—	—	—	—	—	(49.72)	(31.54)	(22.68)		(36.6%)
	Cash flow	—	—	—	—	—	—	—	—	(31.42)	(32.83)	(1.79)		+4.5%
	Capex	—	—	—	—	—	—	—	—	(0.12)	(0.15)	0.00		+25.2%
	Free cash flow	—	—	—	—	—	—	—	—	(31.54)	(32.98)	(1.79)		+4.6%
	Book value	—	—	—	—	—	—	—	—	(26.35)	98.06	7.42		n/m
	Shares, m	—	—	—	—	—	—	—	—	1	2	23		+151.7%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—	0		—
	P/S	—	—	—	—	—	—	—	—	—	—	0		—
	P/B	—	—	—	—	—	—	—	—	—	—	0		—
	EV/Sales	—	—	—	—	—	—	—	—	—	—	0		—
	EV/FCF	—	—	—	—	—	—	—	—	—	—	0		—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	—	—	(30)	(78)	(96)		+163.1%
	Capex	—	—	—	—	—	—	—	—	0	0	0		+215.0%
	Free cash flow	—	—	—	—	—	—	—	—	(30)	(78)	(96)		+163.3%
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	—	—	299	210	282		(29.6%)
	Net debt	—	—	—	—	—	—	—	—	(309)	(216)	(290)		(30.0%)
	Shareholders’ equity	—	—	—	—	—	—	—	—	(25)	233	397		n/m
Returns, %
Returns, %	ROA	—	—	—	—	—	—	—	—	0.00	(26.52)	(37.78)		(26.5) pt
	ROIC	—	—	—	—	—	—	—	—	0.00	(324.62)	(88.12)		(324.6) pt
	ROE	—	—	—	—	—	—	—	—	0.00	127.57	(74.36)		+127.6 pt
People
People	Employees	—	—	—	—	—	—	—	—	—	58	—		—
	Revenue/emp, $m	—	—	—	—	—	—	—	—	—	0.00	—		—

Negative figures in brackets.

estimates

All 10 years →

Fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MNKD MannKind Corporation	$1.2B	— (loss-making)	— (loss-making)	+24.04% (above 0%: growing)	n/m	−267.69% (below 0%: shrinking)	0.00%	(2.14%)	Compare
AVLN Avalyn Pharma Inc.	$1.2B	— (loss-making)	—	—	n/m	—	—	0.00%	Compare
INBX Inhibrx Biosciences, Inc.	$1.2B	— (loss-making)	— (loss-making)	+992.44% (above 0%: growing)	n/m	+0.12% (above 0%: growing)	100.00%	0.00%	Compare
VOR Vor Biopharma Inc.	$1.2B	— (loss-making)	—	—	n/m	−47.59% (below 0%: shrinking)	0.00%	—	Compare
RAPP Rapport Therapeutics, Inc.	$1.1B	— (loss-making)	—	—	n/m	−64.75% (below 0%: shrinking)	100.00%	0.00%	Compare
SGP SpyGlass Pharma, Inc.	$1.1B	— (loss-making)	—	—	n/m	−100.49% (below 0%: shrinking)	—	0.00%	Compare
VSTM Verastem, Inc.	$1.1B	— (loss-making)	— (loss-making)	+113.59% (above 0%: growing)	n/m	+24.50% (above 0%: growing)	0.00%	(313.28%)	Compare
SPTX Seaport Therapeutics, Inc	$1.1B	— (loss-making)	—	—	n/m	−43.81% (below 0%: shrinking)	—	0.00%
JANX Janux Therapeutics, Inc.	$981.9M	— (loss-making)	— (loss-making)	0.00%	n/m	−94.49% (below 0%: shrinking)	100.00%	(336.51%)	Compare
Median of peers	$1.1B	—	—	+68.81%	—	−64.75%	50.00%	0.00%

All 621 Biotechnology stocks →